<DOC>
	<DOCNO>NCT01675349</DOCNO>
	<brief_summary>The objective study determine biologic activity Chenopodium album allergen extract histamine equivalent prick ( HEP ) unit , order use in-house reference preparation ( IHRP ) .</brief_summary>
	<brief_title>Biological Standardization Chenopodium Album Allergen Extract</brief_title>
	<detailed_description>This open , unblinded non-randomized biological assay . The study design slight modification recommendation propose Nordic Guidelines . Four concentration Chenopodium album allergen extract , together positive negative control , use 10 mg/ml histamine dihydrochloride solution glycerinated phenol saline solution , respectively , test every patient duplicate volar surface forearm .</detailed_description>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<criteria>Subject provide write informed consent , appropriately sign date subject ( legal representative , applicable ) . Subject male female race ethnic group . Age &gt; =18 year &lt; =60 year study inclusion day . Positive skin prick test standardize commercially available preparation chenopodium album allergen extract . A positive test specific IgE chenopodium album ( CAPRAST major equal 2 ) . Allergic symptoms pollen season Chenopodium album . Medical history positive allergy inhalation ( rhinitis /or rhinoconjunctivitis and/or asthma ) Chenopodium album . Immunotherapy past 5 year allergen preparation know interfere allergen test . Use drug may interfere skin reaction ( e.g. , antihistamine ) . Treatment follow medication : tricyclic tetracyclic IMAOs antidepressant , bblockers chronic use corticosteroid oral use corticoid via oral parenteral , repeat pattern intermittent ( &gt; 10 mg/d√≠a de prednisone equivalent ) . Women pregnant period breastfeed woman pregnancy test positive visit 2 , prior prick test . Dermographism affect skin area test site either study visit . Atopic dermatitis affect skin area test site either study visit . Urticaria affect skin area test site either study visit . Diseases immune system relevant clinically , autoimmune immunodeficiency . Serious disease control may increase risk safety subject involve study , include , limited following : heart failure , uncontrolled severe respiratory disease , endocrine disease , clinically relevant kidney liver diseases hematological disease . Participation clinical trial within 30 day ( 5 time biological halflife research study product , whichever long ) prior inclusion subject clinical trial . Patients diseases condition limit use adrenaline ( heart disease , severe hypertension , .. ) Severe psychiatric , psychological neurological disorder Abuse alcohol , drug medicine previous year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Standardization</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Skin prick test</keyword>
</DOC>